The Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Rise in Incidence of Retinal Disorders
In developing nations, the pattern of retinal blindness has evolved through time. Prior to ten years ago, hereditary retinal problems were the primary factor in visual impairment brought on by retinal diseases. Retinal blindness has several important and growing causes, including diabetic retinopathy, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). By 2025, there are projected to be 57 million diabetics and 137 million persons over the age of 65 living in India. There will be more than 42 million diabetics in developed countries and more than 82 million in developing countries by the year 2030, according to estimates. In developing nations, the prevalence of AMD ranges from 0.6% to 1.1%, with the exception of Pakistan and Bangladesh. According to WHO standards, there are 1.5 million blind children globally, with 1 million of them living in Asia, 0.3 million in Africa, 0.1 million in Latin America, and 0.1 million elsewhere. ROP can occur anywhere between 21 and 40% of the time in the newborn intensive care unit (NICU) or after a referral to a tertiary care institution. To combat this preventable and treatable retinal cause of blindness, the adoption of measures such as health education and promotion, easily accessible eye care services, infrastructure strengthening, and affordable technologies may be helpful.
What Questions Should You Ask before Buying a Market Research Report?
• How is the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market evolving?
• What is driving and restraining the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market?
• How will each Macular Degeneration (AMD) and Other Retinal Diseases Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Macular Degeneration (AMD) and Other Retinal Diseases Drugs submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Macular Degeneration (AMD) and Other Retinal Diseases Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Macular Degeneration (AMD) and Other Retinal Diseases Drugs projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of Macular Degeneration (AMD) and Other Retinal Diseases Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market?
• Where is the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market today, and over the next 10 years:
• Our 276-page report provides 123 tables and 150 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Macular Degeneration (AMD) and Other Retinal Diseases Drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Indication
• AMD
• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Others
Type
• Wet AMD
• Dry AMD
• Geographic Atrophy
Product
• Lucentis
• Eylea
• Avastin
• Visudyne
• Others
Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Ophthalmic Clinics
• E-commerce Pharmacy
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and xx leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Belgium
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• South East Asia
• Taiwan
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
MEA
• UAE
• South Africa
• Saudi Arabia
• Kuwait
• Oman
• Qatar
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AbbVie
• Alimera Sciences Inc.
• Apellis Pharmaceuticals
• Bausch & Lomb
• Bayer AG
• Belite Bio
• F. Hoffmann-La Roche
• GlaxoSmithKline Pharmaceuticals Ltd.
• GlaxoSmithKline PLC
• Graybug Vision Inc.
• Kubota Vision Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Santen Pharmaceuticals
Overall world revenue for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 in terms of value the market will surpass US$27.0 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 report help you?
In summary, our 270+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 Market, with forecasts for process, upstream, downstream, type and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and xx key national markets – See forecasts for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for xx of the major companies involved in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032: Forecasts by Indication (AMD, Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Others), by Type (Wet AMD, Dry AMD and Geographic Atrophy), by Product (Lucentis, Eylea, Avastin, Visudyne and Others), by Distribution Channel (Hospital Pharmacy, Retail, Pharmacy, Ophthalmic Clinics, E-commerce Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rise in Incidence of Retinal Disorders
3.2.1.2 Upsurge in Geriatric Population
3.2.1.3 Rising Healthcare Expenditure by Various Governments
3.2.2 Market Restraining Factors
3.2.2.1 Increasing Use of Generic Drugs
3.2.2.2 Lack of Awareness Regarding AMD
3.2.2.3 Stringent FDA Regulations
3.2.3 Market Opportunities
3.2.3.1 Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Disorders to Aid Market
3.2.3.2 Untapped Opportunities for the Dry-AMD Treatment
3.2.3.3 Increasing adoption of New Technologies for Treatment
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Indication
4.1 Key Findings
4.2 Indication Segment: Market Attractiveness Index
4.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
4.4 AMD
4.4.1 Market Size by Region, 2022-2032 (US$ bn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 Diabetic Macular Edema: Fastest Growing Segment
4.5.1 Market Size by Region, 2022-2032 (US$ bn)
4.5.2 Market Share by Region, 2022 & 2032 (%)
4.6 Diabetic Retinopathy Market: Coming into Clinical Focus, with DME the Main Target
4.6.1 Market Size by Region, 2022-2032 (US$ bn)
4.6.2 Market Share by Region, 2022 & 2032 (%)
4.7 Retinal Vein Occlusion Market: The Second Most Common Vascular Disease of The Retina
4.7.1 Market Size by Region, 2022-2032 (US$ bn)
4.7.2 Market Share by Region, 2022 & 2032 (%)
4.8 Other Retinal Diseases Market
4.8.1 Market Size by Region, 2022-2032 (US$ bn)
4.8.2 Market Share by Region, 2022 & 2032 (%)
5 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
5.4 Wet AMD
5.4.1 Market Size by Region, 2022-2032 (US$ bn)
5.4.2 Market Share by Region, 2022 & 2032 (%)
5.5 Dry AMD
5.5.1 Market Size by Region, 2022-2032 (US$ bn)
5.5.2 Market Share by Region, 2022 & 2032 (%)
5.6 Geographic Atrophy
5.6.1 Market Size by Region, 2022-2032 (US$ bn)
5.6.2 Market Share by Region, 2022 & 2032 (%)
6 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Product
6.1 Key Findings
6.2 Product Segment: Market Attractiveness Index
6.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
6.4 Lucentis
6.4.1 Market Size by Region, 2022-2032 (US$ bn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Eylea
6.5.1 Market Size by Region, 2022-2032 (US$ bn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Avastin
6.6.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
6.6.2 Roche and Novartis Challenge CATTs Headline Conclusions
6.6.3 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
6.6.4 Will Anything Dislodge Avastin from its Central Position?
6.6.5 Market Size by Region, 2022-2032 (US$ bn)
6.6.6 Market Share by Region, 2022 & 2032 (%)
6.7 Visudyne
6.7.1 Market Size by Region, 2022-2032 (US$ bn)
6.7.2 Market Share by Region, 2022 & 2032 (%)
6.8 Other Drugs
6.8.1 Market Share by Region, 2022 & 2032 (%)
7 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel: Market Attractiveness Index
7.3 Macular Degeneration (AMD) and Other Retinal Disease Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital Pharmacy
7.4.1 Market Size by Region, 2022-2032 (US$ bn)
7.4.2 Market Share by Region, 2022 & 2032 (%)
7.5 Retail Pharmacy
7.5.1 Market Size by Region, 2022-2032 (US$ bn)
7.5.2 Market Share by Region, 2022 & 2032 (%)
7.6 Ophthalmic Clinics
7.6.1 Market Size by Region, 2022-2032 (US$ bn)
7.6.2 Market Share by Region, 2022 & 2032 (%)
7.7 E-commerce Pharmacy
7.7.1 Market Size by Region, 2022-2032 (US$ bn)
7.7.2 Market Share by Region, 2022 & 2032 (%)
8 Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 Wet AMD Segment: Pipeline Analysis
9.1 The Leading Pipeline Candidates
9.2 OPT-302
9.3 GB-102
9.4 Combination of Drugs for the Treatment of AMD and Other Retinal Diseases
9.4.1 Anti-VEGF and Cosopt (Dorzolamide-timolol) Drugs
9.4.2 REGN 910-3 and RG7716
9.4.3 Anti-VEGF and OPT-302 Drugs
9.4.4 Others Combination Therapy Developments
10 Pipeline for Dry AMD Segment
10.1 Apl-2
10.2 Zimura
10.3 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
10.4 Neuroprotection: One of Modern Medicine's Holy Grails
10.5 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
10.6 Elamipretide
10.7 Subthreshold Nanosecond Laser
10.8 Lampalizumab
11 Pipeline for Diabetic Retinopathy Segment
11.1 Steroids in Development for DR
11.2 APX3330
12 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market
12.1 Key Findings
12.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
12.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
12.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
12.5 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
12.6 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
12.7 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Distribution Channel
12.8 U.S.
12.9 Canada
13 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Analysis
13.1 Key Findings
13.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
13.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
13.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
13.5 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
13.6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
13.7 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Distribution Channel
13.8 Germany
13.9 UK
13.10 France
13.11 Italy
13.12 Spain
13.13 Russia
13.14 Belgium
13.15 Rest of Europe
14 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis
14.1 Key Findings
14.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
14.3 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
14.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
14.5 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
14.6 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
14.7 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Distribution Channel
14.8 Japan
14.9 China
14.10 India
14.11 Australia
14.12 South Korea
14.13 Taiwan
14.14 South East Asia
14.15 Rest of Asia Pacific
15 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis
15.1 Key Findings
15.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
15.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
15.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
15.5 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
15.6 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
15.7 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
15.8 Brazil
15.9 Mexico
15.10 Argentina
15.11 Rest of Latin America
16 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis
16.1 Key Findings
16.2 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
16.3 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
16.4 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
16.5 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
16.6 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
16.7 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Distribution Channel
16.8 UAE
16.9 South Africa
16.10 Saudi Arabia
16.11 Kuwait
16.12 Oman
16.13 Qatar
16.14 Rest of MEA
17 Company Profiles
17.1 Competitive Landscape, 2021
17.2 Novartis AG
17.2.1 Company Snapshot
17.2.2 Company Overview
17.2.3 Financial Analysis
17.2.3.1 Net Revenue, 2017-2021
17.2.3.2 R&D, 2017-2021
17.2.3.3 Regional Market Shares, 2021
17.2.4 Product Benchmarking
17.2.5 Strategic Outlook
17.3 F. Hoffmann-La Roche, Ltd.
17.3.1 Company Snapshot
17.3.2 Company Overview
17.3.3 Financial Analysis
17.3.3.1 Net Revenue, 2017-2021
17.3.3.2 R&D, 2017-2021
17.3.3.3 Regional Market Shares, 2021
17.3.4 Product Benchmarking
17.3.5 Strategic Outlook
17.4 GSK plc
17.4.1 Company Snapshot
17.4.2 Company Overview
17.4.3 Financial Analysis
17.4.3.1 Net Revenue, 2017-2021
17.4.3.2 R&D, 2017-2021
17.4.3.3 Regional Market Shares, 2021
17.4.4 Product Benchmarking
17.5 Bayer AG
17.5.1 Company Snapshot
17.5.2 Company Overview
17.5.3 Financial Analysis
17.5.3.1 Net Revenue, 2017-2021
17.5.3.2 R&D, 2017-2021
17.5.3.3 Regional Market Shares, 2021
17.5.4 Product Benchmarking
17.5.5 Strategic Outlook
17.6 Pfizer Inc.
17.6.1 Company Snapshot
17.6.2 Company Overview
17.6.3 Financial Analysis
17.6.3.1 Net Revenue, 2017-2021
17.6.3.2 R&D, 2017-2021
17.6.3.3 Regional Market Shares, 2021
17.6.4 Product Benchmarking
17.6.5 Strategic Outlook
17.7 Regeneron Pharmaceuticals
17.7.1 Company Snapshot
17.7.2 Company Overview
17.7.3 Financial Analysis
17.7.3.1 Net Revenue, 2017-2021
17.7.3.2 R&D, 2017-2021
17.7.3.3 Regional Market Shares, 2021
17.7.4 Product Benchmarking
17.7.5 Strategic Outlook
17.8 Bausch & Lomb Incorporated
17.8.1 Company Snapshot
17.8.2 Company Overview
17.8.3 Product Benchmarking
17.8.4 Strategic Outlook
17.9 Apellis Pharmaceuticals
17.9.1 Company Snapshot
17.9.2 Company Overview
17.9.3 Product Benchmarking
17.9.4 Strategic Outlook
17.10 Santen Pharmaceuticals
17.10.1 Company Snapshot
17.10.2 Company Overview
17.10.3 Financial Analysis
17.10.3.1 Net Revenue, 2017-2021
17.10.3.2 R&D, 2017-2021
17.10.3.3 Regional Market Shares, 2021
17.10.4 Product Benchmarking
17.10.5 Strategic Outlook
17.11 Alimera Sciences
17.11.1 Company Snapshot
17.11.2 Company Overview
17.11.3 Financial Analysis
17.11.3.1 Net Revenue, 2017-2021
17.11.3.2 R&D, 2017-2021
17.11.3.3 Regional Market Shares, 2021
17.11.4 Product Benchmarking
17.11.5 Strategic Outlook
17.12 AbbVie Inc.
17.12.1 Company Snapshot
17.12.2 Company Overview
17.12.3 Financial Analysis
17.12.3.1 Net Revenue, 2017-2021
17.12.3.2 R&D, 2017-2021
17.12.3.3 Regional Market Shares, 2021
17.12.4 Product Benchmarking
17.12.5 Strategic Outlook
17.13 Graybug Vision Inc.
17.13.1 Company Snapshot
17.13.2 Company Overview
17.13.3 Product Benchmarking
17.14 Kubota Vision Inc.
17.14.1 Company Snapshot
17.14.2 Company Overview
17.14.3 Product Benchmarking
17.15Belite Bio Inc.
17.15.1 Company Snapshot
17.15.2 Company Overview
17.15.3 Product Benchmarking
18 Conclusion and Recommendations
18.1 Concluding Remarks from Visiongain
18.2 Recommendations for Market Players
List of Tables
Table 1 Macular Degeneration (AMD) and Other Retinal Diseases Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “V” Shaped Recovery Scenario
Table 3 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “U” Shaped Recovery Scenario
Table 4 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “W” Shaped Recovery Scenario
Table 5 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “L” Shaped Recovery Scenario
Table 6 AMD and Other Disease Drugs Market Forecast by Indication: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 7 AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 8 Diabetic Macular Edema Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 9 Diabetic Retinopathy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 10 Retinal Vein Occlusion Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 11 Other Retinal Diseases Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 12 Global AMD and Other Disease Drugs Market Forecast by Type: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 13 Types of Choroidal Neovascularization in Wet AMD, Description: Approximate Proportion of Cases (%), 2020
Table 14 Wet AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 15 Dry AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 16 Geographic Atrophy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 17 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 18 Lucentis Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 19 Eylea Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 20 Avastin Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 21 Visudyne Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 22 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 23 Global AMD and Other Disease Drugs Market Forecast by Distribution Channel: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 24 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 25 Retail Pharmacies Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 26 Ophthalmic Clinics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 27 E-commerce Pharmacy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 28 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%))
Table 29 Selected R&D Pipeline for wAMD, 2021
Table 30 Selected R&D Pipeline for Dry AMD, 2021
Table 31 Selected R&D Pipeline for DR, 2021
Table 32 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 33 Table 57 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 34 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 35 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 36 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 37 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 38 Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 39 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 40 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 41 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 42 Table 57 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 43 Table 57 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 44 Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 45 UK Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 46 France Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 47 Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 48 Spain Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 49 Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 50 Belgium Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 51 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 52 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 53 Table 57 LA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 54 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 55 Table 57 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 56 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 57 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 58 China Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 59 India Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 60 Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 61 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 62 Taiwan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 63 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 64 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 65 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 66 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 67 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 68 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 69 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 70 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 71 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 72 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 73 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 74 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 75 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 76 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 77 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 78 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 79 UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 80 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 81 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 82 Kuwait Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 83 Oman Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 84 Qatar Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 85 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 86 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Novartis AG: Product Benchmarking
Table 88 Novartis AG: Strategic Outlook
Table 89 F. Hoffmann-La Roche, Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 F. Hoffmann-La Roche: Product Benchmarking
Table 91 F. Hoffmann-La Roche: Strategic Outlook
Table 92 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 GSK plc: Product Benchmarking
Table 94 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Bayer AG: Product Benchmarking
Table 96 Bayer AG: Strategic Outlook
Table 97 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Pfizer Inc.: Product Benchmarking
Table 99 Pfizer Inc.: Strategic Outlook
Table 100 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Regeneron Pharmaceuticals: Product Benchmarking
Table 102 Regeneron Pharmaceuticals: Strategic Outlook
Table 103 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Bausch & Lomb: Product Benchmarking
Table 105 Bausch & Lomb: Strategic Outlook
Table 106 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Apellis Pharmaceuticals: Product Benchmarking
Table 108 Apellis Pharmaceuticals: Strategic Outlook
Table 109 Santen Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Santen Pharmaceuticals: Product Benchmarking
Table 111 Santen Pharmaceuticals: Strategic Outlook
Table 112 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Alimera Sciences: Product Benchmarking
Table 114 Alimera Sciences: Strategic Outlook
Table 115 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 AbbVie Inc.: Product Benchmarking
Table 117 AbbVie Inc.: Strategic Outlook
Table 118 Graybug Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 Graybug Vision Inc.: Product Benchmarking
Table 120 Kubota Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Kubota Vision Inc.: Product Benchmarking
Table 122 Kubota Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Kubota Vision Inc.: Product Benchmarking
List of Figures
Figure 1 Macular Degeneration (AMD) and Other Retinal Diseases Market Segmentation
Figure 2 Macular Degeneration (AMD) and Other Retinal Diseases Market by Indication: Market Attractiveness Index
Figure 3 Macular Degeneration (AMD) and Other Retinal Diseases Market by Type: Market Attractiveness Index
Figure 4 Macular Degeneration (AMD) and Other Retinal Diseases Market by Product: Market Attractiveness Index
Figure 5 Macular Degeneration (AMD) and Other Retinal Diseases Market by Distribution Channel: Market Attractiveness Index
Figure 6 Macular Degeneration (AMD) and Other Retinal Diseases Market Attractiveness Index by Region
Figure 7 Macular Degeneration (AMD) and Other Retinal Diseases Market: Market Dynamics
Figure 8 Macular Degeneration (AMD) and Other Retinal Diseases Market: Porter’s Five Forces Analysis
Figure 9 Macular Degeneration (AMD) and Other Retinal Diseases Market: PEST Analysis
Figure 10 Macular Degeneration (AMD) and Other Retinal Diseases Market by Indication: Market Attractiveness Index
Figure 11 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 12 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Indication, 2022, 2027, 2032 (%)
Figure 13 AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 14 AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 15 Diabetic Macular Edema Market Forecast by Region, 2022-2032 (US$ billion)
Figure 16 Diabetic Macular Edema Market Share Forecast by Region, 2022 & 2032 (%)
Figure 17 Diabetic Retinopathy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 18 Diabetic Retinopathy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 19 Retinal Vein Occlusion Market Forecast by Region, 2022-2032 (US$ billion)
Figure 20 Retinal Vein Occlusion Market Share Forecast by Region, 2022 & 2032 (%)
Figure 21 Other Retinal Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 22 Macular Degeneration (AMD) and Other Retinal Diseases Market by Type: Market Attractiveness Index
Figure 23 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 24 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Type, 2022, 2027, 2032 (%)
Figure 25 Wet AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 26 Wet AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 27 Dry AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 28 Dry AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 29 Geographic Atrophy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 30 Geographic Atrophy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 31 Macular Degeneration (AMD) and Other Retinal Diseases Market by Product: Market Attractiveness Index
Figure 32 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 33 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Product, 2022, 2027, 2032 (%)
Figure 34 Lucentis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 35 Lucentis Market Share Forecast by Region, 2022 & 2032 (%)
Figure 36 Drivers and Restraints for Eylea
Figure 37 Eylea Market Forecast by Region, 2022-2032 (US$ billion)
Figure 38 Eylea Market Share Forecast by Region, 2022 & 2032 (%)
Figure 39 Drivers and Restraints for Avastin
Figure 40 Avastin Market Forecast by Region, 2022-2032 (US$ billion)
Figure 41 Avastin Market Share Forecast by Region, 2022 & 2032 (%)
Figure 42 Visudyne Market Forecast by Region, 2022-2032 (US$ billion)
Figure 43 Visudyne Market Share Forecast by Region, 2022 & 2032 (%)
Figure 44 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 45 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 46 Macular Degeneration (AMD) and Other Retinal Diseases Market by Distribution Channel: Market Attractiveness Index
Figure 47 Macular Degeneration (AMD) and Other Retinal Disease Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 48 Macular Degeneration (AMD) and Other Retinal Disease Market Share Forecast by Distribution Channel, 2022, 2027, 2032 (%)
Figure 49 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 50 Hospital Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 51 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 52 Retail Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 53 Ophthalmic Clinics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 54 Ophthalmic Clinics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 55 E-commerce Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 56 E-commerce Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 57 Macular Degeneration (AMD and Other Retinal Disease Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 58 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%))
Figure 59 North America Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 60 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 61 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 62 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 63 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Indication, 2022 & 2032 (%)
Figure 64 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 65 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 66 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 67 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 68 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 69 Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 70 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 71 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 72 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 73 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 74 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 75 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 76 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Technology, 2022-2032 (US$ billion)
Figure 77 Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 78 UK Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 79 France Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 80 Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 81 Spain Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 82 Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 83 Belgium Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 84 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 85 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 86 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 87 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 88 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 89 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 90 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 91 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 92 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 93 China Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 94 India Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 95 Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 96 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 Taiwan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 98 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 99 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 100 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 101 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 102 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 103 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 104 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 105 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Technology, 2022-2032 (US$ billion)
Figure 106 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 107 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 108 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 109 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 110 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 111 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 112 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 113 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 114 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 115 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 116 UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 117 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 118 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 119 Kuwait Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 120 Oman Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 121 Qatar Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 122 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 123 Macular Degeneration (AMD) and Other Retinal Diseases Market: Company Share/Ranking, 2021
Figure 124 Novartis AG: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 125 Novartis AG: R&D, 2017-2021 (US$ million, AGR%)
Figure 126 Novartis AG: Regional Market Shares, 2021
Figure 127 F. Hoffmann-La Roche: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 128 F. Hoffmann-La Roche: R&D, 2017-2021 (US$ million, AGR%)
Figure 129 F. Hoffmann-La Roche: Regional Market Shares, 2021
Figure 130 GSK plc: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 131 GSK plc: R&D, 2017-2021 (US$ million, AGR%)
Figure 132 GSK plc: Regional Market Shares, 2021
Figure 133 Bayer AG: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 134 Bayer AG: R&D, 2017-2021 (US$ million, AGR%)
Figure 135 Bayer AG: Regional Market Shares, 2021
Figure 136 Pfizer Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 137 Pfizer Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 138 Pfizer Inc.: Regional Market Shares, 2021
Figure 139 Regeneron Pharmaceuticals: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 140 Regeneron Pharmaceuticals: R&D, 2017-2021 (US$ million, AGR%)
Figure 141 Regeneron Pharmaceuticals: Regional Market Shares, 2021
Figure 142 Santen Pharmaceuticals: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 143 Santen Pharmaceuticals: R&D, 2017-2021 (US$ million, AGR%)
Figure 144 Santen Pharmaceuticals: Regional Market Shares, 2021
Figure 145 Alimera Sciences: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 146 Alimera Sciences: R&D, 2017-2021 (US$ million, AGR%)
Figure 147 Alimera Sciences: Regional Market Shares, 2021
Figure 148 AbbVie Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 149 AbbVie Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 150 AbbVie Inc.: Regional Market Shares, 2021
List of Companies Profiled in the Report
AbbVie Inc.
Alimera Sciences Inc.
Apellis Pharmaceuticals
Bausch & Lomb
Bayer AG
Belite Bio
F. Hoffmann-La Roche, Ltd.
Graybug Vision Inc.
GSK plc
Kubota Vision Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals
Santen Pharmaceuticals
List of Other Notable Players
Aerie Pharmaceuticals
Beximco
Carl Zeiss Meditec AG
Chengdu Kanghong Pharmaceutical
Coopervision Company
Edwards Lifesciences Corp
Essilor International S.A.
Gensight Biologics
Glaukos Corporation
Hoya Corporation
Kodiak Sciences Inc
Kubota Pharmaceutical Holdings Co Ltd
Menicon co ltd.
Neurotech
Omeros
OphthaliX /Wize Pharma
Otsuka Pharmaceutical
Phio Pharmaceuticals Corp
Recipharm AB
Staar Surgicals
Topcon Corporation
Veeva System Inc
List of Associations Mentioned in the Report
Central Drugs Standard Control Organization (CDSCO)
Department of Health and Family Welfare
European Commission
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Indian Drug Manufacturer's Association (IDMA)
International Diabetes Federation (IDF)
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Pharmaceutical and Medical Devices Agency (PMDA)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
